SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma

International Journal of Biological Sciences

Volumn 10, Issue 8, 2014, Pages 807-816

  Wang, Qun ^a,b   Zhai, Yang Yang ^b   Dai, Ji Hong ^b   Li, Kun Yu ^b   Deng, Qing ^b   Han, Ze Guang ^a,b,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c Shanghai Jiao Tong University   (China)

Author keywords

Cell cycle; Hepatocellular carcinoma; SAMD9L; Somatic mutation; Wnt pathway

Indexed keywords

TUMOR SUPPRESSOR PROTEIN;

CARCINOGEN TESTING; CELL CYCLE; CELL PROLIFERATION; GENETICS; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MUTATION; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; VIROLOGY;

CARCINOGENICITY TESTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HEPATITIS B VIRUS; HUMANS; IN VITRO TECHNIQUES; LIVER NEOPLASMS; MUTATION; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84906737736     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.9143     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63: 11-30. doi: 10. 3322/caac. 21166.
2. Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma. World journal of gastroenterology: WJG. 2008; 14: 1720-33.
3. Tirnitz-Parker JE, Glanfield A, Olynyk JK, Ramm GA. Iron and hepatic carcinogenesis. Critical reviews in oncogenesis. 2013; 18: 391-407.
4. McKillop IH, Schrum LW. Role of alcohol in liver carcinogenesis. Seminars in liver disease. 2009; 29: 222-32. doi: 10. 1055/s-0029-1214377.
5. Moudgil V, Redhu D, Dhanda S, Singh J. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer. 2013; 32: 165-75.
6. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Human mutation. 2003; 21: 201-16. doi: 10. 1002/humu. 10176.
7. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95: 8847-51.
8. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009; 457: 200-4. doi: 10. 1038/nature07475.
9. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nature genetics. 2012; 44: 1117-21. doi: 10. 1038/ng. 2391.
10. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature genetics. 2011; 43: 828-9. doi: 10. 1038/ng. 903.
11. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature genetics. 2012; 44: 694-8. doi: 10. 1038/ng. 2256.
12. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature genetics. 2012; 44: 760-4. doi: 10. 1038/ng. 2291.
13. Knudsen ES, Gopal P, Singal AG. The Changing Landscape of Hepatocellular Carcinoma: Etiology, Genetics, and Therapy. The American journal of pathology. 2014; 184: 574-83. doi: 10. 1016/j. ajpath. 2013. 10. 028.
14. Li CF, MacDonald JR, Wei RY, Ray J, Lau K, Kandel C, et al. Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. BMC genomics. 2007; 8: 92. doi: 10. 1186/1471-2164-8-92.
15. Hershkovitz D, Gross Y, Nahum S, Yehezkel S, Sarig O, Uitto J, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. The Journal of investigative dermatology. 2011; 131: 662-9. doi: 10. 1038/jid. 2010. 387.
16. Lemos de Matos A, Liu J, McFadden G, Esteves PJ. Evolution and divergence of the mammalian SAMD9/SAMD9L gene family. BMC evolutionary biology. 2013; 13: 121. doi: 10. 1186/1471-2148-13-121.
17. Asou H, Matsui H, Ozaki Y, Nagamachi A, Nakamura M, Aki D, et al. Identification of a common microdeletion cluster in 7q21. 3 subband among patients with myeloid leukemia and myelodysplastic syndrome. Biochemical and biophysical research communications. 2009; 383: 245-51. doi: 10. 1016/j. bbrc. 2009. 04. 004.
18. Chefetz I, Ben Amitai D, Browning S, Skorecki K, Adir N, Thomas MG, et al. Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein. The Journal of investigative dermatology. 2008; 128: 1423-9. doi: 10. 1038/sj. jid. 5701203.
19. Dereure O. [SAMD9 mutation in normophosphatemic familial tumoral calcinosis]. Annales de dermatologie et de venereologie. 2007; 134: 505.
20. Topaz O, Indelman M, Chefetz I, Geiger D, Metzker A, Altschuler Y, et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. American journal of human genetics. 2006; 79: 759-64. doi: 10. 1086/508069.
21. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS medicine. 2007; 4: e176. doi: 10. 1371/journal. pmed. 0040176.
22. Pappas DJ, Coppola G, Gabatto PA, Gao F, Geschwind DH, Oksenberg JR, et al. Longitudinal system-based analysis of transcriptional responses to type I interferons. Physiological genomics. 2009; 38: 362-71. doi: 10. 1152/physiolgenomics. 00058. 2009.
23. Nagamachi A, Matsui H, Asou H, Ozaki Y, Aki D, Kanai A, et al. Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy. Cancer cell. 2013; 24: 305-17. doi: 10. 1016/j. ccr. 2013. 08. 011.
24. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome research. 2013; 23: 1422-33. doi: 10. 1101/gr. 154492. 113.
25. Campbell RM, Tummino PJ. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. The Journal of clinical investigation. 2014; 124: 64-9. doi: 10. 1172/JCI71605.
26. Choi JD, Lee JS. Interplay between Epigenetics and Genetics in Cancer. Genomics & informatics. 2013; 11: 164-73. doi: 10. 5808/GI. 2013. 11. 4. 164.
27. Moeini A, Cornella H, Villanueva A. Emerging Signaling Pathways in Hepatocellular Carcinoma. Liver cancer. 2012; 1: 83-93. doi: 10. 1159/000342405.
28. Dong H, Zhang H, Liang J, Yan H, Chen Y, Shen Y, et al. Digital karyotyping reveals probable target genes at 7q21. 3 locus in hepatocellular carcinoma. BMC medical genomics. 2011; 4: 60. doi: 10. 1186/1755-8794-4-60.
29. Diez-Villasenor C, Guzman NM, Almendros C, Garcia-Martinez J, Mojica FJ. CRISPR-spacer integration reporter plasmids reveal distinct genuine acquisition specificities among CRISPR-Cas I-E variants of Escherichia coli. RNA biology. 2013; 10: 792-802. doi: 10. 4161/rna. 24023.
30. Djordjevic M, Djordjevic M, Severinov K. CRISPR transcript processing: a mechanism for generating a large number of small interfering RNAs. Biology direct. 2012; 7: 24. doi: 10. 1186/1745-6150-7-24.
31. Liu J, Wennier S, Zhang L, McFadden G. M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells. Journal of virology. 2011; 85: 3270-82. doi: 10. 1128/JVI. 02243-10.
32. Zhang LK, Chai F, Li HY, Xiao G, Guo L. Identification of host proteins involved in Japanese encephalitis virus infection by quantitative proteomics analysis. Journal of proteome research. 2013; 12: 2666-78. doi: 10. 1021/pr400011k.
33. Sun B, Karin M. Inflammation and liver tumorigenesis. Frontiers of medicine. 2013; 7: 242-54. doi: 10. 1007/s11684-013-0256-4.
34. Lata J. Chronic liver diseases as liver tumor precursors. Dig Dis. 2010; 28: 596-9. doi: 10. 1159/000320057.
35. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clinical reviews in allergy & immunology. 2009; 36: 4-12. doi: 10. 1007/s12016-008-8091-0.
36. Martin M, Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome medicine. 2012; 4: 8. doi: 10. 1186/gm307.
37. Gao B, Wang H, Lafdil F, Feng D. STAT proteins-key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. Journal of hepatology. 2012; 57: 430-41. doi: 10. 1016/j. jhep. 2012. 01. 029.
38. Cairo S, Buendia MA. How transient becomes stable: an epigenetic switch linking liver inflammation and tumorigenesis. Journal of hepatology. 2012; 57: 910-2. doi: 10. 1016/j. jhep. 2012. 05. 017.